Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients

NCT00939991 is registered in ClinicalTrials.gov with Katy Peters as lead sponsor.

NCT NCT00939991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00939991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients
Lead sponsor
Katy Peters
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2009
Completion date
April 30, 2013
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, glioblastoma